ArticleOpen forum infectious diseases2020
Case Report: Successful Rescue Therapy of Extensively Drug-Resistant
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort.Antibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Treatment Options for Multidrug Resistant Gram-Negative Pathogens in Bone and Joint Infections.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Comprehensive Approaches to CombattingAntibiotics (Basel, Switzerland) · 2024Review
- In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol.The Journal of antibiotics · 2024Article
- Successful outpatient parenteral antibiotic therapy with cefiderocol for osteomyelitis caused by multi-drug resistant Gram-negative bacteria: a case report.JAC-antimicrobial resistance · 2024Article
- Case Report: Hip arthroplasty after fracture-related joint infection caused by extensively drug-resistantFrontiers in surgery · 2024Article
- Cefiderocol and Sulbactam-Durlobactam against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Carbapenem-ResistantOpen forum infectious diseases · 2023Article
- [Clinical experience using cefiderocol].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023Review
- The Role of Novel Antibiotics in the Management of Diabetic Foot Infection.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Review
- The role of cefiderocol in clinical practice.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Clinical experience of cefiderocol.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence.Antibiotics (Basel, Switzerland) · 2022Review
- Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Review
- Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.Frontiers in pharmacology · 2022Review
- New Perspectives on Antimicrobial Agents: Cefiderocol.Antimicrobial agents and chemotherapy · 2021Review
- Compassionate use of cefiderocol for carbapenem-resistantJAC-antimicrobial resistance · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Cefiderocol is a novel catechol siderophore cephalosporin antibiotic developed to treat resistant gram-negative infections. We describe its successful use as rescue therapy, combined with surgical debridement, to treat a patient with osteomyelitis due to extensively drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.